Slocum Gordon & Co LLP Sells 2,961 Shares of Johnson & Johnson $JNJ

Slocum Gordon & Co LLP cut its position in Johnson & Johnson (NYSE:JNJ) by 6.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,864 shares of the company’s stock after selling 2,961 shares during the quarter. Johnson & Johnson accounts for 5.4% of Slocum Gordon & Co LLP’s holdings, making the stock its 6th largest holding. Slocum Gordon & Co LLP’s holdings in Johnson & Johnson were worth $6,700,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of JNJ. Semmax Financial Advisors Inc. increased its stake in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth approximately $35,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $48,000. Vermillion & White Wealth Management Group LLC boosted its position in Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after buying an additional 150 shares during the period. Finally, Gladwyn Financial Advisors Inc. acquired a new position in shares of Johnson & Johnson in the second quarter worth $71,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Bank of America lifted their target price on Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a report on Wednesday, October 15th. The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Raymond James Financial raised their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday, October 15th. Finally, Guggenheim increased their price objective on shares of Johnson & Johnson from $206.00 to $227.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $207.55.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $211.65 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $212.27. The firm’s 50 day moving average is $196.09 and its two-hundred day moving average is $177.25. The firm has a market capitalization of $509.93 billion, a P/E ratio of 20.43, a P/E/G ratio of 2.36 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.